1
|
Ligia S, Passucci M, Assanto GM, D'Elia GM, Annechini G, De Propris MS, Martelli M, Del Giudice I, Tiacci E, Pulsoni A. Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome. Br J Haematol 2024; 204:1288-1292. [PMID: 38050458 DOI: 10.1111/bjh.19237] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Revised: 11/15/2023] [Accepted: 11/21/2023] [Indexed: 12/06/2023]
Abstract
First-line purine nucleoside analogues (PNAs) in hairy cell leukaemia (HCL) allow deep and long-lasting responses. We retrospectively analysed 53 HCL patients treated frontline with cladribine and assessed for response at 2 and 6 months after treatment to evaluate the kinetics of response. The estimated median progression-free survival was significantly different according to the degree of residual HCL infiltrate detected by immunohistochemistry at the bone marrow biopsy at 2 months (≤5% vs. >5%, 247 vs. 132 months, respectively, p = 0.033), but not at 6 months (p = 0.79). Our data suggest a favourable prognostic impact of early marrow HCL clearance in patients treated with cladribine.
Collapse
Affiliation(s)
- S Ligia
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - M Passucci
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - G M Assanto
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - G M D'Elia
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - G Annechini
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - M S De Propris
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - M Martelli
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - I Del Giudice
- Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy
| | - E Tiacci
- Department of Medicine and Surgery, Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy
| | - A Pulsoni
- Hematology, Department of Translational and Precision Medicine, Sapienza University, S.M. Goretti Hospital, Latina, Italy
| |
Collapse
|
2
|
Moia R, Favini C, Talotta D, Sagiraju S, Bruna R, Dondolin R, Della Starza I, Soscia R, Andorno A, Mercalli F, Deambrogi C, Rasi S, Petrucci L, Bellissimo T, Luciano Boldorini R, Di Rocco A, Del Giudice I, Martelli M, Foà R, Gaidano G. P1281: LIQUID BIOPSY PROVIDES COMPLEMENTARY INFORMATION TO TISSUE BIOPSIES FOR THE MOLECULAR CLASSIFICATION OF DLBCL PATIENTS. Hemasphere 2022. [PMCID: PMC9431283 DOI: 10.1097/01.hs9.0000847988.92666.b7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Assanto GM, Ciotti G, Brescini M, Agrippino R, Lapietra G, De Luca ML, Annechini G, D'Elia GM, Chiaravalloti A, Del Giudice I, Pulsoni A. FAVOURABLE PROGNOSTIC ROLE OF HIGH BASAL MAXIMAL STANDARDIZED UPTAKE VALUE IN FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.95_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- G. M. Assanto
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - G. Ciotti
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - M. Brescini
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - R. Agrippino
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - G. Lapietra
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - M. L. De Luca
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - G. Annechini
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - G. M. D'Elia
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - A. Chiaravalloti
- Nuclear medicine Department of Biomedicine and Prevention Nuclear Medicine University Tor Vergata Rome Italy
| | - I. Del Giudice
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| | - A. Pulsoni
- Haematology Department of Translational and Precision Medicine Sapienza University of Rome Rome Italy
| |
Collapse
|
4
|
Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann Oncol 2019; 29:966-972. [PMID: 29365086 DOI: 10.1093/annonc/mdy021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase followed by progression and others do not progress for decades. The latter two subgroups usually display mutated IGHV genes and a favorable FISH profile. Patients and methods Patients with absence of disease progression for over 10 years (10-34) from diagnosis were defined as ultra-stable CLL (US-CLL). Forty US-CLL underwent extensive characterization including whole exome sequencing (WES), ultra-deep sequencing and copy number aberration (CNA) analysis to define their unexplored genetic landscape. Microarray analysis, comparing US-CLL with non-US-CLL with similar immunogenetic features (mutated IGHV/favorable FISH), was also carried out to recognize US-CLL at diagnosis. Results WES was carried out in 20 US-CLL and 84 non-silent somatic mutations in 78 genes were found. When re-tested in a validation cohort of 20 further US-CLL, no recurrent lesion was identified. No clonal mutations of NOTCH1, BIRC3, SF3B1 and TP53 were found, including ATM and other potential progression driving mutations. CNA analysis identified 31 lesions, none with known poor prognostic impact. No novel recurrent lesion was identified: most cases showed no lesions (38%) or an isolated del(13q) (31%). The expression of 6 genes, selected from a gene expression profile analysis by microarray and quantified by droplet digital PCR on a cohort of 79 CLL (58 US-CLL and 21 non-US-CLL), allowed to build a decision-tree capable of recognizing at diagnosis US-CLL patients. Conclusions The genetic landscape of US-CLL is characterized by the absence of known unfavorable driver mutations/CNA and of novel recurrent genetic lesions. Among CLL patients with favorable immunogenetics, a decision-tree based on the expression of 6 genes may identify at diagnosis patients who are likely to maintain an indolent disease for decades.
Collapse
Affiliation(s)
- S Raponi
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - I Del Giudice
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Marinelli
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Wang
- Division of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong
| | - L Cafforio
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - C Ilari
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Messina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Bonina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Bordyuh
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - P Mariglia
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - N Peragine
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - F R Mauro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Chiaretti
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Molica
- Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - M Gentile
- Hematology Uni, Department of Hemato-Oncology, Ospedale Annunziata, Cosenza, Italy
| | - A Visentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - L Trentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - G M Rigolin
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - A Cuneo
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F Diop
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - D Rossi
- Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - R Foà
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
| |
Collapse
|
5
|
Federico M, Mannina D, Versari A, Ferrero S, Marcheselli L, Boccomini C, Dondi A, Tucci A, Guerra L, Galimberti S, Cavallo F, Olivieri J, Corradini P, Arcaini L, Chauvie S, Del Giudice I, Rusconi C, Pinto A, Molinari A, Pulsoni A, Merli M, Kovalchuk S, Nassi L, Bolis S, Gattei V, Manni M, Pileri S, Brugiatelli M, Luminari S. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2629] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Federico
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - D. Mannina
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - A. Versari
- Nuclear Medicine Unit; AUSL-IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - S. Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Division of Hematology; University of Torino; Torino Italy
| | - L. Marcheselli
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - C. Boccomini
- SC Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Dondi
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - A. Tucci
- SC Ematologia; ASST-Spedali Civili; Brescia Italy
| | - L. Guerra
- Nuclear Medicine Unit; San Gerardo Hospital; Monza Italy
| | - S. Galimberti
- Division of Hematology, Department of Oncology; Santa Chiara Hospital; Pisa Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - J. Olivieri
- Clinica Ematologica; Centro Trapianti e Terapie Cellulari “C. Melzi”, DAME, ASUI; Udine Italy
| | - P. Corradini
- Department of Oncology and Hematology; Fondazione Istituto Nazionale dei Tumori Milano University of Milano; Milano Italy
| | - L. Arcaini
- Department of Molecular Medicine; University of Pavia, Division of Hematology, Fondazione IRCCS Policlinico S. Matteo; Pavia Italy
| | - S. Chauvie
- Medical Physics Unit; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - I. Del Giudice
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - C. Rusconi
- Division of Hematology; ASST Grande ospedale Metropolitano Niguarda; Milano Italy
| | - A. Pinto
- Department of Hematology and Developmental Therapeutics; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’ IRCCS; Napoli Italy
| | - A. Molinari
- UO Ematologia; OC Rimini AUSL Romagna; Rimini Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - M. Merli
- Hematology; University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria; Varese Italy
| | - S. Kovalchuk
- Ematologia; Università degli Studi di Firenze; Firenze Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - S. Bolis
- Hematolgy Unit; ASST-Monza; Monza Italy
| | - V. Gattei
- Clinical and Experimental Onco-Haematology Unit; Centro di Riferimento Oncologico, IRCCS; Aviano Italy
| | - M. Manni
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - S. Pileri
- Divisione di Diagnosi Ematopatologica; Istituto Europeo di Oncologia; Milano Italy
| | - M. Brugiatelli
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - S. Luminari
- S.C. Ematologia; Arcispedale S. Maria Nuova-IRCCS; Reggio Emilia Italy
| |
Collapse
|
6
|
Genuardi E, Barbero D, Dogliotti I, Mantoan B, Drandi D, Gambella M, Zaccaria GM, Monitillo L, Della Starza I, Cavalli M, De Novi LA, Ciabatti E, Grassi S, Gazzola A, Mannu C, Del Giudice I, Galimberti S, Agostinelli C, Piccaluga PP, Ladetto M, Ferrero S. Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis. Int J Lab Hematol 2017; 40:201-208. [PMID: 29205868 DOI: 10.1111/ijlh.12766] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2017] [Accepted: 10/26/2017] [Indexed: 12/01/2022]
Abstract
INTRODUCTION The high-throughput era remarkably changed molecular laboratory practice. Actually, the increasing number of processed samples requires to reduce the risk of operator biases, by automating or simplifying as much as possible both the analytical and the pre-analytical phases. Minimal residual disease (MRD) studies in hematology often require a simultaneous processing of many bone marrow and peripheral blood samples from patients enrolled in prospective, multicenter, clinical trials, monitored at several planned time points. METHODS In this study, we demonstrate that red blood cell lysis (RBL) pre-analytical procedure can replace the time-consuming Ficoll stratification as cell recovering step. Here, we show a MRD comparison study using both total white blood cells and mononuclear cells recovered by the 2 procedures from 46 follicular lymphoma (FL), 15 multiple myeloma (MM), and 11 mantle cell lymphoma (MCL) patients enrolled in prospective clinical trials. RESULTS The experiments were performed in the 4 laboratories of the Fondazione Italiana Linfomi (FIL) MRD Network and showed superimposable results, in terms of good correlation (R = 0.87) of the MRD data obtained by recovering blood cells by the 2 approaches. CONCLUSION Based on these results, the FIL MRD Network suggests to optimize the pre-analytical phases introducing RBL approach for cell recovery in the clinical trials including MRD analysis.
Collapse
Affiliation(s)
- E. Genuardi
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | - D. Barbero
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | - I. Dogliotti
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | - B. Mantoan
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | - D. Drandi
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | - M. Gambella
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | - G. M. Zaccaria
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
- Division of Hematology; Department of Oncology; Santa Chiara Hospital; Pisa Italy
- Department of Medical Biotechnologies; University of Siena; Siena Italy
- Hematopathology Section; Department of Experimental, Diagnostic, and Specialty Medicine; S. Orsola-Malpighi Hospital; Bologna University; Bologna Italy. Division of Hematology; Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo; Alessandria Italy. Department of Electronics and Telecommunications; Politecnico di Torino; Torino Italy
| | - L. Monitillo
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | - I. Della Starza
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - M. Cavalli
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - L. A. De Novi
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - E. Ciabatti
- Division of Hematology; Department of Oncology; Santa Chiara Hospital; Pisa Italy
| | - S. Grassi
- Division of Hematology; Department of Oncology; Santa Chiara Hospital; Pisa Italy
- Department of Medical Biotechnologies; University of Siena; Siena Italy
| | - A. Gazzola
- Hematopathology Section; Department of Experimental, Diagnostic, and Specialty Medicine; S. Orsola-Malpighi Hospital; Bologna University; Bologna Italy
| | - C. Mannu
- Hematopathology Section; Department of Experimental, Diagnostic, and Specialty Medicine; S. Orsola-Malpighi Hospital; Bologna University; Bologna Italy
| | - I. Del Giudice
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - S. Galimberti
- Division of Hematology; Department of Oncology; Santa Chiara Hospital; Pisa Italy
| | - C. Agostinelli
- Hematopathology Section; Department of Experimental, Diagnostic, and Specialty Medicine; S. Orsola-Malpighi Hospital; Bologna University; Bologna Italy
| | - P. P. Piccaluga
- Hematopathology Section; Department of Experimental, Diagnostic, and Specialty Medicine; S. Orsola-Malpighi Hospital; Bologna University; Bologna Italy
| | - M. Ladetto
- Division of Hematology; Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| | - S. Ferrero
- Department of Molecular Biotechnologies and Health Sciences; Division of Hematology; University of Torino; Torino Italy
| | | |
Collapse
|
7
|
Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia 2017; 32:543-546. [PMID: 28924243 DOI: 10.1038/leu.2017.292] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- I Del Giudice
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - G M Rigolin
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - S Raponi
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - L Cafforio
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - C Ilari
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - J Wang
- Divisions of Life Science and Biomedical Engineering, Hong Kong University of Science and Technology, Hong Kong, China
| | - M Bordyuh
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Marinelli
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Nanni
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Filetti
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - A Bardi
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Tammiso
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Volta
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - M Negrini
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Saccenti
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F R Mauro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - D Rossi
- Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Cuneo
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - R Foà
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| |
Collapse
|
8
|
Pulsoni A, Della Starza I, Cappelli L, Tosti M, Annechini G, Cavalli M, De Novi L, D'Elia G, Grapulin L, Guarini A, Del Giudice I, Foa' R. MINIMAL RESIDUAL DISEASE (MRD) IN EARLY STAGE FOLLICULAR LYMPHOMA CAN PREDICT PROGNOSIS AND DRIVE RITUXIMAB TREATMENT AFTER RADIOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Pulsoni
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - I. Della Starza
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L.V. Cappelli
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - M.E. Tosti
- National Center for Global Health; National Institute of Health; Rome Italy
| | - G. Annechini
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - M. Cavalli
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L.A. De Novi
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - G.M. D'Elia
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L. Grapulin
- Radiologic Science; Sapienza University; Rome Italy
| | - A. Guarini
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - I. Del Giudice
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - R. Foa'
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| |
Collapse
|
9
|
Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Cresta S, Famà R, Deambrogi C, Greco M, Fangazio M, Ciardullo C, Piranda D, Casaluci GM, Messina M, Giudice ID, Chiaretti S, Marinelli M, Guarini A, Foà R, Gaidano G. The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. Leuk Suppl 2012; 1:S26-8. [PMID: 27175239 DOI: 10.1038/leusup.2012.16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Next-generation whole-exome sequencing has revealed two novel genes, namely NOTCH1 and SF3B1, whose mutations predict poor outcome and preferentially associate with chemorefractory chronic lymphocytic leukemia (CLL). Analysis of 539 CLL cases documents that NOTCH1 mutations i) represent one of the most frequent cancer gene mutations involved at presentation; ii) cluster with cases harboring trisomy 12 and tend to be mutually exclusive with TP53 disruption among genetic subgroups; iii) identify high-risk patients showing poor survival similar to that associated with TP53 abnormalities; and iv) exert a prognostic role independent of widely accepted clinical and genetic risk factors. Mutations of SF3B1, a splicing factor that is a critical component of the spliceosome, recurrently associate with fludarabine-refractory CLL, occur at a low rate at CLL presentation and have a minor role in Richter transformation, corroborating the notion that CLL histological shift is molecularly distinct from chemorefractory progression without the Richter transformation.
Collapse
Affiliation(s)
- D Rossi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Rasi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - V Spina
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - A Bruscaggin
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Monti
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Cresta
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - R Famà
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - C Deambrogi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Greco
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Fangazio
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - C Ciardullo
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - D Piranda
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - G M Casaluci
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Messina
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - I D Giudice
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - S Chiaretti
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - M Marinelli
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - A Guarini
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - R Foà
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy; Fondazione Eleonora Lorillard Spencer Cenci, Sapienza University, Rome, Italy
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| |
Collapse
|
10
|
Osuji N, Del Giudice I, Matutes E, Morilla A, Owusu-Ankomah K, Morilla R, Dunlop A, Catovksy D. CD52 expression in T-cell large granular lymphocyte leukemia – Implications for treatment with alemtuzumab. Leuk Lymphoma 2009; 46:723-7. [PMID: 16019510 DOI: 10.1080/10428190500052156] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Few reports on the successful treatment of T-cell large granular lymphocyte (LGL) leukemia with the humanized anti-CD52 monoclonal antibody alemtuzumab are emerging in the literature. The expression of CD52 by LGLs has not been previously investigated. Using semi-quantitative 2- and 3-color flow cytometry, we documented the expression of CD52 in 100% of abnormal cells in T-cell LGL leukemia (n = 11) and natural killer (NK) cell LGL leukemia (n = 2), and showed no significant difference in CD52 expression between T-cell prolymphocytic leukemia (PLL) and T-cell LGL leukemia. Higher CD52 expression has been noted in responders to alemtuzumab in T-cell PLL and in chronic lymphocytic leukemia (CLL), a B-cell disorder. The strong and consistent expression of CD52 shown here highlights the potential role of alemtuzumab in the treatment of refractory T-cell LGL leukemia and possibly aggressive NK cell leukemia.
Collapse
MESH Headings
- Alemtuzumab
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Neoplasm/therapeutic use
- Antigens, CD/biosynthesis
- Antigens, Neoplasm/biosynthesis
- Antineoplastic Agents/therapeutic use
- CD52 Antigen
- Flow Cytometry
- Glycoproteins/biosynthesis
- Humans
- Immunophenotyping
- Leukemia, Lymphoid/drug therapy
- Leukemia, Lymphoid/immunology
- Leukemia, T-Cell/drug therapy
- Leukemia, T-Cell/immunology
Collapse
Affiliation(s)
- N Osuji
- Section of Haemato-Oncology, Royal Marsden NHS Trust and Institute of Cancer Research, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Mauro FR, Coluzzi S, Del Giudice I, Armiento D, De Propris MS, Starza ID, De Nicolo' MC, Guarini A, Girelli G, Foa' R. Evidence of a sub-clinical lymphoproliferative disease in patients with ‘idiopathic‘ autoimmune hemolytic anemia. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Del Giudice I, Davis Z, Matutes E, Osuji N, Parry-Jones N, Morilla A, Brito-Babapulle V, Oscier D, Catovsky D. IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). Leukemia 2006; 20:1231-7. [PMID: 16642047 DOI: 10.1038/sj.leu.2404238] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
B-prolymphocytic leukemia (B-PLL) is a rare disease with poor prognosis. To further characterize the biological features of this disease, we analyzed immunoglobulin heavy chain (IgVH) mutations, ZAP-70 and CD38 in 19 cases with de novo B-PLL. Immunoglobulin heavy chain genes analysis showed an unmutated pattern (>98% homology to germ line) in 9/17 cases (53%), with 100% homology in eight. In the remaining, it ranged from 90 to 97.4%, with three cases slightly mutated (98-95%) and five heavily mutated (<95%). All B-PLL utilized members of VH3 (11/17) and VH4 (6/17) families, with V3-23, V4-59 and V4-34 gene accounting for more than half of them, regardless of mutational status. ZAP-70, assessed by flow cytometry, ranged from 1 to 91% cells, being > or =20% in 57% of cases. CD38 ranged from 1 to 99% (median 21%). There was no correlation between IgVH status and ZAP-70 or CD38 expression, but male gender and del(17p) were more common in the unmutated group. Neither IgVH mutations, CD38 expression nor del(17p) influenced patients' outcome. Unexpectedly, ZAP-70+ B-PLL patients survived longer (40 months) than ZAP-70- B-PLL (8 months). B-PLL appears biologically heterogeneous regarding IgVH mutations, ZAP-70 and CD38 expression, showing a pattern distinct from that of other lymphoproliferative disorders.
Collapse
Affiliation(s)
- I Del Giudice
- Section of Haemato-Oncology--Institute of Cancer Research, Sutton, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Abstract
We describe a case of natural killer (NK) cell leukemia with acute presentation, systemic symptoms and hepatosplenomegaly. The uniform and aberrant phenotype of NK cells with infiltration of bone marrow and spleen was in keeping with a malignant diagnosis. Aggressive presentation was demonstrated by marked constitutional symptoms and significant tumor burden (liver, spleen, blood, bone marrow). The subsequent clinical course has been indolent, but this may have been influenced by treatment. Treatment consisted sequentially of splenectomy, intravenous pentostatin and the combination of cyclosporine A and recombinant human erythropoietin and has resulted in survival of over 48 months. We discuss the difficulties in the diagnosis of this condition, explore possible causes of cytopenia(s), and highlight the role of immunosuppression in controlling disease manifestations in large granular lymphocyte proliferative disorders.
Collapse
Affiliation(s)
- N Osuji
- Section of Haemato-Oncology, Royal Marsden NHS Trust/Institute of Cancer Research, London, UK
| | | | | | | | | | | |
Collapse
|
14
|
Del Giudice I, Iori AP, Mengarelli A, Testi AM, Romano A, Cerretti R, Macrì F, Iacobini M, Arcese W. Allogeneic stem cell transplant from HLA-identical sibling for chronic granulomatous disease and review of the literature. Ann Hematol 2003; 82:189-92. [PMID: 12634956 DOI: 10.1007/s00277-002-0590-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2002] [Accepted: 11/07/2002] [Indexed: 10/25/2022]
Abstract
Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by an abnormal function of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in the phagocytic cells, which results in an increased susceptibility to severe bacterial and fungal infections. We report on a 12-year-old boy with X-linked CGD who was successfully treated with allogeneic bone marrow transplantation from an HLA-identical sibling following a conditioning regimen consisting of busulphan (BU, 16 mg/kg) and cyclophosphamide (CY, 200 mg/kg). At >2 years from transplant, the boy is in excellent clinical and hematological condition with full chimerism. Our patient is the 24th case of CGD transplanted from an HLA-identical sibling. A review of the literature revealed that 20 of 24 CGD patients are alive and disease free 1-7 years after transplant. Most of these patients were conditioned with the BUCY combination, which should be considered the recommended regimen.
Collapse
Affiliation(s)
- I Del Giudice
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Via Benevento 6, 00161 Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Arcese W, Guglielmi C, Iori AP, Screnci M, Carmini D, Testi AM, Moleti ML, Mengarelli A, Del Giudice I, Cimino G, Elia L, Rapanotti MC, Perrone P, Laurenti L, Gentile G, Boecklin F, Romano A, De Felice L, Mandelli F. Umbilical cord blood transplant from unrelated HLA-mismatched donors in children with high risk leukemia. Bone Marrow Transplant 1999; 23:549-54. [PMID: 10217184 DOI: 10.1038/sj.bmt.1701615] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
In the last 3 years, 14 children with high-risk leukemia (11 ALL, 2 AML and 1 CML) underwent cord blood transplantation from unrelated HLA-mismatched donors at a median of 99 days from the start of search. Eight patients were transplanted in second CR, one in accelerated phase, three at relapse and two patients in first CR. Conditioning regimen (fractionated TBI, etoposide, CY and anti-lymphocyte serum) and prophylaxis of GVHD (CsA and 6-methylprednisolone) were identical for all patients. Neutrophils >0.5x10(9)/l were reached at a median of 33 days from transplant, but in four cases we observed an autologous hematopoietic reconstitution (three spontaneous, one after autologous BM rescue). Acute and chronic GVHD were observed in 10/14 and 3/8 evaluable cases, respectively. Three patients died of transplant-related toxicity and three patients relapsed. The probabilities of event-free, disease-free and overall survival were 50, 53 and 64%, respectively. Cord blood transplant from HLA-mismatched unrelated donor is a valid option for the treatment of children with high-risk leukemia. With our eligibility criteria, conditioning regimen and prophylaxis of graft-versus-host disease, the main obstacles to successful transplant were represented by graft failure and fatal acute GVHD.
Collapse
Affiliation(s)
- W Arcese
- Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza Rome, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Haematologica 1997; 82:664-7. [PMID: 9499665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND AND OBJECTIVE The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL). In an attempt to minimize the non-hematologic toxicity and obtain a potent antileukemic effect, MSKCC activated a pilot study in previously treated adult ALL, using HD-ARA-C combined with idarubicin administered as a single high-dose infusion. We herein report our experience with a series of pediatric and adult high risk ALL and NHL patients treated with the protocol above, which confirms its feasibility, response rate and individual compliance. METHODS In a clinical phase II study, the combination of a single high dose (HD) of idarubicin and HD cytosine-arabinoside (ARA-C), as designed at the Memorial Sloan Kettering Cancer Center, was applied to 70 adults and children with refractory or early relapse acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic non-Hodgkin's lymphoma (NHL). Therapy consisted of HD-ARA-C 3 g/m2/d on days 1-5, idarubicin 40 mg/m2 on day 3, prophylactic intrathecal methotrexate on days 1 and 4, and G-CSF 5 mg/kg/d s.c. from day 7 to hematopoietic reconstitution (PMN > 0.5 x 10(9)/L). RESULTS Fifty-five of the 70 patients (78%) achieved complete remission (CR), four died in aplasia due to infection and 11 were non-responders. Recovery of blood counts occurred at a median of 21 days from the start of treatment. Non-hematologic side effects were extremely limited and consisted predominantly of infections. INTERPRETATION AND CONCLUSIONS In view of the highly unfavorable series of patients selected, this study confirms the feasibility and antileukemic activity of the HD-idarubicin + HD-ARA-C combination in patients with refractory and early relapse ALL and NHL. The excellent tolerance to this regimen does not preclude bone marrow transplantation as post-remission treatment.
Collapse
Affiliation(s)
- A M Testi
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Testi AM, Moleti ML, Giona F, Annino L, Chiaretti S, Del Giudice I, Todisco E, D'Elia G, Ferrari A, Arcese W, Mandelli F. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome. Haematologica 1997; 82:19-22. [PMID: 9402749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND AND OBJECTIVE The anthracycline analogue idarubicin, either alone or in combination with other antineoplastic drugs, has shown antileukemic activity in relapsed and refractory acute lymphoblastic leukemia (ALL). In an attempt to minimize the non-hematologic toxicity and obtain a potent antileukemic effect, MSKCC activated a pilot study in previously treated adult ALL, using HD-ARA-C combined with idarubicin administered as a single high-dose infusion. We herein report our experience with a series of pediatric and adult high risk ALL and NHL patients treated with the protocol above, which confirms its feasibility, response rate and individual compliance. METHODS In a clinical phase II study the combination of a single high dose (HD) idarubicin and HD cytosine-arabinoside (ARA-C), as designed at the Memorial Sloan Kettering Cancer Center, was applied to 70 adults and children with refractory or early relapse acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic non-Hodgkin's lymphoma (NHL). Therapy consisted of HD-ARA-C 3 g/m2/d on days 1-5, idarubicin 40 mg/m2 on day 3, prophylactic intrathecal methotrexate on days 1 and 4, and G-CSF 5 mg/kg/d s.c. from day 7 to hematopoietic reconstitution (PMN > 0.5 x 10(9)/L). RESULTS Fifty-five of the 70 patients (78%) achieved complete remission (CR), four died in aplasia due to infection and 11 were non-responders. Recovery of blood counts occurred at a median of 21 days from the start of treatment. Non-hematologic side effects were extremely limited and consisted predominantly of infections. INTERPRETATION AND CONCLUSIONS In view of the highly unfavorable series of patients selected, this study confirms the feasibility and antileukemic activity of the HD-idarubicin + HD- ARA-C combination in patients with refractory and early relapse ALL and NHL. The excellent tolerance to this regimen does not preclude bone marrow transplantation as post-remission treatment.
Collapse
Affiliation(s)
- A M Testi
- Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|